HK1249103B - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use - Google Patents
Polycyclic-carbamoylpyridone compounds and their pharmaceutical use Download PDFInfo
- Publication number
- HK1249103B HK1249103B HK18108873.5A HK18108873A HK1249103B HK 1249103 B HK1249103 B HK 1249103B HK 18108873 A HK18108873 A HK 18108873A HK 1249103 B HK1249103 B HK 1249103B
- Authority
- HK
- Hong Kong
- Prior art keywords
- compound
- mmol
- group
- mixture
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142338P | 2015-04-02 | 2015-04-02 | |
| US62/142,338 | 2015-04-02 | ||
| PCT/US2016/025740 WO2016161382A1 (en) | 2015-04-02 | 2016-04-01 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19129461.0A Division HK40005949B (en) | 2015-04-02 | 2018-07-09 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19129461.0A Addition HK40005949B (en) | 2015-04-02 | 2018-07-09 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1249103A1 HK1249103A1 (en) | 2018-10-26 |
| HK1249103B true HK1249103B (en) | 2020-02-07 |
Family
ID=55754453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18108873.5A HK1249103B (en) | 2015-04-02 | 2016-04-01 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Country Status (20)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107674086B (zh) | 2012-12-21 | 2020-03-31 | 吉利德科学公司 | 多环-氨基甲酰基吡啶酮化合物及其药物用途 |
| TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| HK1249103B (en) * | 2015-04-02 | 2020-02-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| AU2019277547B2 (en) | 2018-05-31 | 2024-10-10 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| MX2020012176A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de carbamoilpiridona. |
| CN119462659A (zh) * | 2019-03-22 | 2025-02-18 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| WO2021093846A1 (zh) * | 2019-11-13 | 2021-05-20 | 上海拓界生物医药科技有限公司 | 新型四环杂环化合物及其药物用途 |
| US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| BR112022015771A2 (pt) * | 2020-02-24 | 2022-10-11 | Gilead Sciences Inc | Compostos tetracíclicos para tratar a infecção por hiv |
| JP7691494B2 (ja) * | 2020-09-30 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | 架橋三環式カルバモイルピリドン化合物及びその使用 |
| CN114426540B (zh) * | 2020-10-29 | 2024-04-26 | 上海拓界生物医药科技有限公司 | 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用 |
| WO2022089562A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海拓界生物医药科技有限公司 | 抑制基因缺陷的hiv病毒的用途 |
| PE20231297A1 (es) | 2021-01-19 | 2023-08-22 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN115015310B (zh) * | 2022-05-23 | 2024-12-10 | 宁波大学 | 一种巯基化合物的分析方法 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| AP2001002169A0 (en) | 1998-12-25 | 2001-06-30 | Shionogi & Co | Aromatic heterocycle compounds having hiv intergrase inhibiting activities |
| EP1297834A4 (en) | 2000-06-14 | 2007-05-09 | Shionogi & Co | ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| CN1564685A (zh) | 2001-10-03 | 2005-01-12 | Ucb公司 | 吡咯烷酮衍生物 |
| CN1700918B (zh) | 2001-10-26 | 2011-06-08 | P·安杰莱蒂分子生物学研究所 | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| EP1549315A4 (en) | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
| KR100665919B1 (ko) | 2002-11-20 | 2007-03-08 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도 |
| PL378368A1 (pl) | 2003-01-14 | 2006-04-03 | Gilead Sciences, Inc. | Kompozycje i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| CA2554120A1 (en) | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors |
| WO2005086700A2 (en) | 2004-03-09 | 2005-09-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
| ES2529038T3 (es) | 2004-05-07 | 2015-02-16 | Merck Sharp & Dohme Corp. | Inhibidores de la integrasa de VIH |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| EP3287130A1 (en) | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| ATE505196T1 (de) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| US7858788B2 (en) * | 2005-02-21 | 2010-12-28 | Shionogi & Co., Ltd. | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| UA96568C2 (en) * | 2005-04-28 | 2011-11-25 | Глаксосмиткляйн Ллк | Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor |
| ES2743531T3 (es) | 2005-04-28 | 2020-02-19 | Viiv Healthcare Co | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| JP2009502964A (ja) | 2005-07-27 | 2009-01-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体 |
| US8188271B2 (en) | 2005-10-27 | 2012-05-29 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| HRP20080313A2 (en) | 2005-12-30 | 2008-11-30 | Gilead Sciences | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| IN2014CN00532A (cg-RX-API-DMAC7.html) | 2006-03-06 | 2015-04-03 | Japan Tobacco Inc | |
| AU2007223260C1 (en) | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100092427A1 (en) | 2006-07-19 | 2010-04-15 | The University Of Georgia Research Foundation | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy |
| SG10201501782UA (en) | 2006-09-12 | 2015-05-28 | Gilead Sciences Inc | Process and intermediates for preparing integrase inhibitors |
| WO2008048538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
| AP3915A (en) | 2007-02-23 | 2016-11-29 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| EP2167089A1 (en) | 2007-06-29 | 2010-03-31 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| KR20100040892A (ko) | 2007-06-29 | 2010-04-21 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011814A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| US8217034B2 (en) | 2008-07-25 | 2012-07-10 | Shionogi & Co., Ltd. | Chemical compounds |
| ES2395705T3 (es) | 2008-07-25 | 2013-02-14 | Glaxosmithkline Llc | Compuestos químicos |
| CA2744019C (en) | 2008-12-11 | 2017-03-14 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| PE20160180A1 (es) | 2010-01-27 | 2016-05-04 | Viiv Healthcare Co | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. |
| SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| EA201291300A1 (ru) | 2010-07-02 | 2013-06-28 | Джилид Сайэнс, Инк. | Производные нафт-2-илуксусной кислоты для лечения спида |
| JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ抗ウイルス化合物としての２−キノリニル−酢酸誘導体 |
| JP5636054B2 (ja) | 2010-08-05 | 2014-12-03 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法 |
| PT2620436T (pt) | 2010-09-24 | 2018-09-28 | Shionogi & Co | Profármaco de derivado de carbamoilo piridona policíclica substituída |
| ES2615734T3 (es) | 2011-04-21 | 2017-06-08 | Gilead Sciences, Inc. | Compuestos de benzotiazol y su uso farmacéutico |
| US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
| KR20140090197A (ko) | 2011-10-12 | 2014-07-16 | 시오노기세야쿠 가부시키가이샤 | 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체 |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDEINDION DERIVATIVES AS HIV INTEGRASE INHIBITORS |
| CA2878699C (en) | 2012-08-03 | 2018-09-11 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| KR20150093819A (ko) | 2012-12-14 | 2015-08-18 | 글락소스미스클라인 엘엘씨 | 약제 조성물 |
| US9714243B2 (en) * | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| US20160000721A1 (en) | 2012-12-21 | 2016-01-07 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| CN107674086B (zh) | 2012-12-21 | 2020-03-31 | 吉利德科学公司 | 多环-氨基甲酰基吡啶酮化合物及其药物用途 |
| US10087178B2 (en) | 2012-12-27 | 2018-10-02 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor |
| US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| NO2865735T3 (cg-RX-API-DMAC7.html) * | 2013-07-12 | 2018-07-21 | ||
| PL3252058T3 (pl) * | 2013-07-12 | 2021-07-19 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| TN2016000090A1 (en) | 2013-09-27 | 2017-07-05 | Merck Sharp & Dohme | Substituted quinolizine derivatives useful as hiv integrase inhibitors. |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| HK1249103B (en) * | 2015-04-02 | 2020-02-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2016
- 2016-04-01 HK HK18108873.5A patent/HK1249103B/en unknown
- 2016-04-01 ES ES18207888T patent/ES2837383T3/es active Active
- 2016-04-01 ES ES16716776T patent/ES2718410T3/es active Active
- 2016-04-01 PT PT182078881T patent/PT3466490T/pt unknown
- 2016-04-01 EA EA201791872A patent/EA201791872A1/ru unknown
- 2016-04-01 TR TR2019/05009T patent/TR201905009T4/tr unknown
- 2016-04-01 WO PCT/US2016/025740 patent/WO2016161382A1/en not_active Ceased
- 2016-04-01 AU AU2016244035A patent/AU2016244035B2/en active Active
- 2016-04-01 US US15/089,342 patent/US9630978B2/en active Active
- 2016-04-01 CN CN201680025671.0A patent/CN107531727B/zh active Active
- 2016-04-01 SI SI201630216T patent/SI3277691T1/sl unknown
- 2016-04-01 BR BR112017020837-7A patent/BR112017020837A2/pt not_active IP Right Cessation
- 2016-04-01 KR KR1020177031329A patent/KR101982431B1/ko active Active
- 2016-04-01 EP EP18207888.1A patent/EP3466490B1/en active Active
- 2016-04-01 EP EP16716776.6A patent/EP3277691B1/en active Active
- 2016-04-01 NZ NZ735575A patent/NZ735575A/en not_active IP Right Cessation
- 2016-04-01 PT PT16716776T patent/PT3277691T/pt unknown
- 2016-04-01 SG SG11201707905WA patent/SG11201707905WA/en unknown
- 2016-04-01 JP JP2017549768A patent/JP6402259B2/ja active Active
- 2016-04-01 CA CA2980362A patent/CA2980362C/en active Active
- 2016-04-01 SI SI201630966T patent/SI3466490T1/sl unknown
- 2016-04-01 EP EP20167360.5A patent/EP3736274A1/en not_active Withdrawn
- 2016-04-01 CN CN201911067354.7A patent/CN110790773A/zh active Pending
- 2016-04-01 KR KR1020197014269A patent/KR20190057158A/ko not_active Withdrawn
- 2016-04-01 MX MX2017012393A patent/MX2017012393A/es unknown
- 2016-04-01 PL PL16716776T patent/PL3277691T3/pl unknown
-
2017
- 2017-09-18 IL IL254552A patent/IL254552A0/en unknown
-
2018
- 2018-09-10 JP JP2018168811A patent/JP6745308B2/ja active Active
- 2018-09-27 AU AU2018236826A patent/AU2018236826B2/en active Active
-
2019
- 2019-12-17 AU AU2019283812A patent/AU2019283812A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236826B2 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK1249103A1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| EP3237416B1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK1244000A1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK40005949B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK40005949A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK40015662A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK1260851A1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| HK1248688B (zh) | 多环氨甲醯基吡啶酮化合物及其药物用途 |